Business
Sai Parenterals buys major stake in Bion Therapeutics to expand domestic market reach
Reported by Manish Reddy (Senior Writer) · The Hindu - Business ·

Sai Parenterals is buying a majority stake in Bion Therapeutics India through its subsidiary SP Analytics for an undisclosed amount.
Deal Details
The all-cash transaction involves a signed definitive agreement, and Bion will become a step-down subsidiary upon completion expected this month. The buyout adds 16 established brands and about 250 field staff to strengthen market presence. Production of Bion's portfolio will move progressively into Sai Parenterals' own facilities, which hold WHO-GMP and TGA-Australia accreditations. Anil Kumar Karusala, chairman and managing director of Sai Parenterals, stated that Bion provides the route to take developed and manufactured products directly to the Indian market.
Context
Corporate acquisitions in the pharmaceutical sector often aim to secure direct manufacturing control and expand distribution reach. Moving production to in-house facilities helps companies manage supply chains and quality standards more closely.
More in Business
BusinessSource: The HinduImportant
NMDC Plans Big Push to Grow Iron Ore Pellet Production Capacity
Reported by Rohit Yadav (Staff Writer) · The Hindu - Business ·
